VEGFR2; MET; AXL; MER; TYRO3

Class

Multi-receptor tyrosine kinase inhibitor (next-generation cabozantinib analog, shorter half-life)

Pathway

Angiogenesis blockade plus MET/TAM-family kinase signaling inhibition

This mechanism targets a group of receptor tyrosine kinases that tumors rely on both to grow new blood supply and to become invasive when that blood supply is threatened. VEGFR2 sits on the surface of blood vessel lining cells and, when activated, drives angiogenesis, the formation of new vessels that solid tumors need to grow beyond a small size. MET, the receptor for hepatocyte growth factor, promotes tumor cell proliferation, survival, and movement, and is frequently upregulated when tumors are deprived of oxygen. AXL, MER, and TYRO3 form the TAM family of receptors, which support cell survival, invasion, and suppression of antitumor immune activity. Blocking VEGFR2 alone can starve a tumor of blood supply, but tumors often respond by activating MET and TAM signaling to invade surrounding tissue and evade the immune system. An inhibitor that acts on all five targets aims to close off both the angiogenic supply route and these compensatory invasive and immune-evasive pathways simultaneously. This broad-spectrum approach is relevant across solid tumors where blood vessel growth, invasive spread, and immune evasion together drive disease progression, including cancers of the kidney, liver, and other vascularized or metastasis-prone tissues.